Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.21
ETRM's Cash-to-Debt is ranked lower than
57% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ETRM: 1.21 )
Ranked among companies with meaningful Cash-to-Debt only.
ETRM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.8  Med: 4.27 Max: No Debt
Current: 1.21
Equity-to-Asset 0.11
ETRM's Equity-to-Asset is ranked lower than
91% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ETRM: 0.11 )
Ranked among companies with meaningful Equity-to-Asset only.
ETRM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.24  Med: 0.25 Max: 0.62
Current: 0.11
-0.24
0.62
Piotroski F-Score: 2
Altman Z-Score: -44.42
Beneish M-Score: -1.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3301.76
ETRM's Operating Margin % is ranked lower than
97% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. ETRM: -3301.76 )
Ranked among companies with meaningful Operating Margin % only.
ETRM' s Operating Margin % Range Over the Past 10 Years
Min: -9543.49  Med: -8396.99 Max: -7250.48
Current: -3301.76
-9543.49
-7250.48
Net Margin % -3236.27
ETRM's Net Margin % is ranked lower than
96% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ETRM: -3236.27 )
Ranked among companies with meaningful Net Margin % only.
ETRM' s Net Margin % Range Over the Past 10 Years
Min: -8732.53  Med: -8137.97 Max: -7543.41
Current: -3236.27
-8732.53
-7543.41
ROE % -1668.35
ETRM's ROE % is ranked lower than
99% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. ETRM: -1668.35 )
Ranked among companies with meaningful ROE % only.
ETRM' s ROE % Range Over the Past 10 Years
Min: -493.35  Med: -140.32 Max: -77.38
Current: -1668.35
-493.35
-77.38
ROA % -191.72
ETRM's ROA % is ranked lower than
94% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. ETRM: -191.72 )
Ranked among companies with meaningful ROA % only.
ETRM' s ROA % Range Over the Past 10 Years
Min: -196.35  Med: -83.42 Max: -60.09
Current: -191.72
-196.35
-60.09
ROC (Joel Greenblatt) % -7511.50
ETRM's ROC (Joel Greenblatt) % is ranked lower than
95% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. ETRM: -7511.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ETRM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6079.21  Med: -2401.78 Max: -575.02
Current: -7511.5
-6079.21
-575.02
3-Year Revenue Growth Rate -25.10
ETRM's 3-Year Revenue Growth Rate is ranked lower than
86% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. ETRM: -25.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ETRM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -25.1
Current: -25.1
3-Year EBITDA Growth Rate -21.30
ETRM's 3-Year EBITDA Growth Rate is ranked lower than
85% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. ETRM: -21.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ETRM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.2 Max: -21.3
Current: -21.3
3-Year EPS without NRI Growth Rate -21.60
ETRM's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ETRM: -21.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ETRM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -54.9 Max: -21.6
Current: -21.6
GuruFocus has detected 4 Warning Signs with EnteroMedics Inc $ETRM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ETRM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ETRM Guru Trades in

Q2 2016

ETRM Guru Trades in Q2 2016

Jim Simons 250,538 sh (New)
» More
Q3 2016

ETRM Guru Trades in Q3 2016

Jim Simons 3,931,399 sh (+1469.18%)
» More
Q4 2016

ETRM Guru Trades in Q4 2016

Jim Simons 162,765 sh (+189.80%)
» More
» Details

Insider Trades

Latest Guru Trades with ETRM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:OTCPK:TLTFF, OTCPK:ZMSPF, NAS:MDVX, OTCPK:SNWV, OTCPK:VASO, NAS:KOOL, OTCPK:VICA, NAS:AMDA, OTCPK:DIZTF, OTCPK:CRVW, AMEX:HRT, OTCPK:RMSL, NAS:LLIT, NAS:PHMD, OTCPK:ZYXI, NAS:RWLK, OTCPK:PHMZF, NAS:AHPI, NAS:DYNT, OTCPK:PYNGF » details
Traded in other countries:BY8E.Germany,
EnteroMedics Inc is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders.

EnteroMedics Inc was incorporated in Minnesota on December 19, 2002 and later reincorporated in Delaware on July 22, 2004. It is a medical device company with approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries that recognize the European CE Mark. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's proprietary neuroblocking technology, VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company's initial product, the Maestro Rechargeable System uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has regulatory approval to sell its product in Australia, the European Economic Area and other countries that recognize the European CE Mark and do not have any other source of revenue. The Company relies on third-party manufacturers and suppliers for the production of its Maestro Rechargeable System. The Company competes in the market for obesity treatment with surgical obesity procedures and various devices used to implement neurostimulation and gastric stimulation systems. The Company also competes against the manufacturers of pharmaceuticals that are directed at treating obesity. The Company's opeartors include: Roche, GlaxoSmithKline, Arena Pharmaceuticals, Inc., VIVUS, Inc. and Orexigen Therapeutics, Inc. The Company also competes with several private early-stage companies developing neurostimulation devices for application to the gastric region and related nerves for the treatment of obesity. The Company has 32 national stage patent applications, including applications in Australia, China, India, Europe and Japan, one granted Chinese application and one granted application in Japan. In addition, the Company is the exclusive licensee to three U.S. patents owned by the Mayo Foundation for Medical Education and Research, which are unrelated to the Company's VBLOC therapy. Maestro Rechargeable System is regulated by the FDA as a medical device under the Federal Food, Drug, and Cosmetic Act (FFDCA) and the regulations promulgated under the FFDCA.

Ratios

vs
industry
vs
history
PB Ratio 5.18
ETRM's PB Ratio is ranked lower than
76% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. ETRM: 5.18 )
Ranked among companies with meaningful PB Ratio only.
ETRM' s PB Ratio Range Over the Past 10 Years
Min: 1.68  Med: 4.25 Max: 60.56
Current: 5.18
1.68
60.56
PS Ratio 1.24
ETRM's PS Ratio is ranked higher than
72% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. ETRM: 1.24 )
Ranked among companies with meaningful PS Ratio only.
ETRM' s PS Ratio Range Over the Past 10 Years
Min: 0.42  Med: 247.98 Max: 1113.18
Current: 1.24
0.42
1113.18
EV-to-EBIT -1.01
ETRM's EV-to-EBIT is ranked lower than
99.99% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. ETRM: -1.01 )
Ranked among companies with meaningful EV-to-EBIT only.
ETRM' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.1  Med: -1.6 Max: 0.1
Current: -1.01
-6.1
0.1
EV-to-EBITDA -1.02
ETRM's EV-to-EBITDA is ranked lower than
99.99% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 15.79 vs. ETRM: -1.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
ETRM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.2  Med: -1.6 Max: 0.1
Current: -1.02
-6.2
0.1
Current Ratio 1.20
ETRM's Current Ratio is ranked lower than
83% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. ETRM: 1.20 )
Ranked among companies with meaningful Current Ratio only.
ETRM' s Current Ratio Range Over the Past 10 Years
Min: 1.01  Med: 3.24 Max: 9.46
Current: 1.2
1.01
9.46
Quick Ratio 0.93
ETRM's Quick Ratio is ranked lower than
81% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. ETRM: 0.93 )
Ranked among companies with meaningful Quick Ratio only.
ETRM' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.07 Max: 9.46
Current: 0.93
0.81
9.46
Days Inventory 1.00
ETRM's Days Inventory is ranked higher than
99% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. ETRM: 1.00 )
Ranked among companies with meaningful Days Inventory only.
ETRM' s Days Inventory Range Over the Past 10 Years
Min: 1840.73  Med: 2867.28 Max: 3893.82
Current: 1
1840.73
3893.82
Days Sales Outstanding 88.26
ETRM's Days Sales Outstanding is ranked lower than
67% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. ETRM: 88.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
ETRM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.03  Med: 66.77 Max: 72.5
Current: 88.26
61.03
72.5
Days Payable 601.85
ETRM's Days Payable is ranked higher than
99% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. ETRM: 601.85 )
Ranked among companies with meaningful Days Payable only.
ETRM' s Days Payable Range Over the Past 10 Years
Min: 502.24  Med: 519.37 Max: 536.49
Current: 601.85
502.24
536.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -35.70
ETRM's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ETRM: -35.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ETRM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -137.1  Med: -26 Max: 0
Current: -35.7
-137.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 49.83
ETRM's Price-to-Net-Current-Asset-Value is ranked lower than
95% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 6.59 vs. ETRM: 49.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ETRM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.04  Med: 6.49 Max: 561.19
Current: 49.83
0.04
561.19
Price-to-Tangible-Book 5.18
ETRM's Price-to-Tangible-Book is ranked lower than
65% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 4.24 vs. ETRM: 5.18 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ETRM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.03  Med: 5.76 Max: 89.97
Current: 5.18
0.03
89.97
Price-to-Median-PS-Value 0.01
ETRM's Price-to-Median-PS-Value is ranked higher than
100% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. ETRM: 0.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ETRM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.83 Max: 2.72
Current: 0.01
0.01
2.72
Earnings Yield (Greenblatt) % -99.00
ETRM's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. ETRM: -99.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ETRM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1720.5  Med: 13654.7 Max: 44250.5
Current: -99
1720.5
44250.5

More Statistics

Revenue (TTM) (Mil) $0.79
EPS (TTM) $ -176.43
Beta2.82
Short Percentage of Float68.02%
52-Week Range $1.75 - 88.55
Shares Outstanding (Mil)3.95

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1 3 6
EPS ($) -2.30 -1.14 -0.85
EPS without NRI ($) -2.30 -1.14 -0.85
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ETRM

Headlines

Articles On GuruFocus.com
Kevin Douglas Bets on EnteroMedics; Popeyes and AMERCO Top Estimates May 28 2015 
Canaccord Genuity Remains Bullish on EnteroMedics Following Q4 Earnings Feb 19 2015 
Analysts Are Bullish On EnteroMedics Following FDA Approval Of Obesity Treatment Jan 16 2015 
EnteroMedics Inc. Reports Operating Results (10-K) Mar 07 2011 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 08 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 06 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) May 07 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 16 2009 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 07 2009 
EnteroMedics Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
ENTEROMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 21 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating EnteroMedics Inc. for Potential... Feb 21 2017
EnteroMedics Regains Compliance With Nasdaq Listing Requirement Feb 21 2017
ENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Feb 14 2017
EnteroMedics Announces Publication of Three-Year Data from vBloc Diabetic Patient Study in Journal... Feb 09 2017
ENTEROMEDICS INC Files SEC form 8-K, Other Events Jan 31 2017
ENTEROMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 24 2017
EnteroMedics Announces Closing of $19.0 Million Underwritten Public Offering and Full Exercise of... Jan 23 2017
Biotech Movers: Illumina, Inc. (ILMN) And EnteroMedics Inc (ETRM) Jan 12 2017
Stock Market Roundup, Jan. 10: NVDA Self-Driving Cars, ETRM Soars Jan 10 2017
Still Struggling to Put Money to Work Jan 10 2017
EnteroMedics and GenVec Post Substantial Gains as the NASDAQ is Pushed to Record High Jan 10 2017
Biotech Movers: EnteroMedics Inc (ETRM) And Stemline Therapeutics Inc (STML) Jan 09 2017
Bullish and Bearish Reversals in the Market Jan 09 2017
ENTEROMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 05 2017
Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday Jan 05 2017
EnteroMedics Announces vBloc® Neurometabolic Therapy Now Available at MedStar Health and Roper St.... Jan 05 2017
EnteroMedics Announces vBloc® Neurometabolic Therapy Now Available at MedStar Health and Roper St.... Jan 05 2017
EnteroMedics Announces Retirement of All Senior Convertible Notes Dec 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)